Article

Stress-blocker may restore hair

They weren’t looking for it, but researchers at the University of California, Los Angeles, say they have uncovered a promising hair-loss treatment, the online New York Times reports.

Related Videos
Marah C. Hehemann, MD, answers a question during a video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Oliver Sartor, MD, is featured in this series.
Diverse group of doctors | © Flamingo Images - stock.adobe.com
Man talking with a doctor | Image Credit: © RFBSIP - stock.adobe.com
1 KOL is featured in this series.
Related Content
FDA grants Regenerative Medicine Advanced Therapy designation to ALLO-316 for RCC
October 29th 2024

FDA grants Regenerative Medicine Advanced Therapy designation to ALLO-316 for RCC

Hannah Clarke Gina Mauro
The RMAT designation is supported by interim data from the ongoing phase 1 TRAVERSE trial.
Key updates from the AUA/ASRM male infertility guideline amendment
September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff
In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.
UGN-102 data published in Journal of Urology as FDA weighs NMIBC approval
October 28th 2024

UGN-102 data published in Journal of Urology as FDA weighs NMIBC approval

Hannah Clarke
The phase 3 ENVISION trial met its primary end point by demonstrating a 79.6% complete response rate at 3 months following the first instillation of the therapy.
Speaking of Urology: Dr. Winter on the use of vaginal estrogen
July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff
In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.
FDA approves oral sulopenem for uncomplicated urinary tract infection
Published: October 25th 2024 | Updated: October 25th 2024

FDA approves oral sulopenem for uncomplicated urinary tract infection

Hannah Clarke
The approval is supported by data from the phase 3 SURE 1 and REASSURE trials.
OASIS: Efficacy of Revi System for urgency incontinence maintained at 2 years
October 25th 2024

OASIS: Efficacy of Revi System for urgency incontinence maintained at 2 years

Hannah Clarke
The therapeutic response rate was 79% at 24 months, which is comparable to the rates seen at 6 months (78%) and 12 months (82%).
© 2024 MJH Life Sciences

All rights reserved.